Advanced Lipoprotein Testing: Recommendations Based on Current Evidence

Endocrinology and Metabolism Clinics of North America

Volumn 38, Issue 1, 2009, Pages 1-31

  Lau, Joe F ^a   Smith, Donald A ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Advanced lipoprotein testing; Apolipoprotein B; LDL particle number; LDL particle size; Non HDL cholesterol; Nuclear magnetic resonance spectroscopy (NMR); Segmented gradient gel electrophoresis; Vertical density gradient ultracentrifugation

Indexed keywords

LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; HEALTH SURVEY; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; REVIEW; ULTRACENTRIFUGATION;

ANIMALS; APOLIPOPROTEINS B; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; ELECTROPHORESIS; EVIDENCE-BASED MEDICINE; GUIDELINES AS TOPIC; HUMANS; LIPOPROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; PREDICTIVE VALUE OF TESTS; ULTRACENTRIFUGATION;

EID: 59649119715     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2008.11.008     Document Type: Review

References (55)

1. Illingworth D.R. Management of hypercholesterolemia. Med Clin North Am 84 1 (2000) 23-42
2. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 14 (2005) 1425-1435
3. Expert Panel on Detection EaToHBCiA. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 19 (2001) 2486-2497
4. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 44 3 (2004) 720-732
5. Smith Jr. S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, And Blood Institute. Circulation 113 19 (2006) 2363-2372
6. Bachorik P.S., Lovejoy K.L., Carroll M.D., et al. Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem 43 12 (1997) 2364-2378
7. Mora S., Szklo M., Otvos J.D., et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 192 1 (2007) 211-217
8. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 6 (1972) 499-502
9. Campos H., Khoo C., and Sacks F.M. Diurnal and acute patterns of postprandial apolipoprotein B-48 in VLDL, IDL, and LDL from normolipidemic humans. Atherosclerosis 181 2 (2005) 345-351
10. Sniderman A.D., Furberg C.D., Keech A., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361 9359 (2003) 777-780
11. Marcovina S.M., Albers J.J., Kennedy H., et al. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material. Clin Chem 40 4 (1994) 586-592
12. Grundy S.M. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 106 20 (2002) 2526-2529
13. De Lalla O.F., and Gofman J.W. Ultracentrifugal analysis of serum lipoproteins. Methods Biochem Anal 1 (1954) 459-478
14. Chung B.H., Wilkinson T., Geer J.C., et al. Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. J Lipid Res 21 3 (1980) 284-291
15. Marcovina S.M., Albers J.J., Scanu A.M., et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 46 12 (2000) 1956-1967
16. 100 by the vertical auto profile method. Clinical Chemistry 53 S6 (2007) A41
17. Williams P.T., Superko H.R., Haskell W.L., et al. Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler Thromb Vasc Biol 23 2 (2003) 314-321
18. St-Pierre A.C., Ruel I.L., Cantin B., et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 104 19 (2001) 2295-2299
19. Otvos J.D., Jeyarajah E.J., Bennett D.W., et al. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 38 9 (1992) 1632-1638
20. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 269 23 (1993) 3015-3023
21. Liu J., Sempos C.T., Donahue R.P., et al. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol 98 10 (2006) 1363-1368
22. Farwell W.R., Sesso H.D., Buring J.E., et al. Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol as a risk factor for a first nonfatal myocardial infarction. Am J Cardiol 96 8 (2005) 1129-1134
23. Rallidis L.S., Pitsavos C., Panagiotakos D.B., et al. Non-high density lipoprotein cholesterol is the best discriminator of myocardial infarction in young individuals. Atherosclerosis 179 2 (2005) 305-309
24. Bittner V., Hardison R., Kelsey S.F., et al. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 106 20 (2002) 2537-2542
25. von M.D., Langer R.D., and Barrett-Connor E. Sex and time differences in the associations of non-high-density lipoprotein cholesterol versus other lipid and lipoprotein factors in the prediction of cardiovascular death (the Rancho Bernardo Study). Am J Cardiol 91 11 (2003) 1311-1315
26. Shai I., Rimm E.B., Hankinson S.E., et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation 110 18 (2004) 2824-2830
27. Walldius G., Jungner I., Holme I., et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 9298 (2001) 2026-2033
28. Benn M., Nordestgaard B.G., Jensen G.B., et al. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol 27 3 (2007) 661-670
29. Pischon T., Girman C.J., Sacks F.M., et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112 22 (2005) 3375-3383
30. Simes R.J., Marschner I.C., Hunt D., et al. Relationship between lipid levels and clinical outcomes in the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?. Circulation 105 10 (2002) 1162-1169
31. Gotto Jr. A.M., Whitney E., Stein E.A., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101 5 (2000) 477-484
32. Kastelein J.J., van der Steeg W.A., Holme I., et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117 23 (2008) 3002-3009
33. Hsia S.H., Pan D., Berookim P., et al. A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease. Am J Cardiol 98 8 (2006) 1047-1052
34. Sharrett A.R., Ballantyne C.M., Coady S.A., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 104 10 (2001) 1108-1113
35. Kuller L., Arnold A., Tracy R., et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 22 7 (2002) 1175-1180
36. Rosenson R.S., Otvos J.D., and Freedman D.S. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 90 2 (2002) 89-94
37. St-Pierre A.C., Cantin B., Dagenais G.R., et al. Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men. Am J Cardiol 97 7 (2006) 997-1001
38. St-Pierre A.C., Cantin B., Dagenais G.R., et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec cardiovascular study. Arterioscler Thromb Vasc Biol 25 3 (2005) 553-559
39. El H.K., van der Steeg W.A., Stroes E.S., et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. J Am Coll Cardiol 49 5 (2007) 547-553
40. van der Steeg W.A., Boekholdt S.M., Stein E.A., et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 146 9 (2007) 640-648
41. Ingelsson E., Schaefer E.J., Contois J.H., et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 298 7 (2007) 776-785
42. Cromwell W.C., Otvos J.D., Keyes M.J., et al. LDL particle number and risk of future cardiovascular disease in the Framingham offspring study-implications for LDL management. Journal of Clinical Lipidology 1 (2007) 583-592
43. Ridker P.M., Rifai N., Cook N.R., et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294 3 (2005) 326-333
44. Blake G.J., Otvos J.D., Rifai N., et al. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106 15 (2002) 1930-1937
45. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 6 (1999) 410-418
46. Robins S.J., Collins D., Wittes J.T., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285 12 (2001) 1585-1591
47. Otvos J.D., Collins D., Freedman D.S., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113 12 (2006) 1556-1563
48. Lu W., Resnick H.E., Jablonski K.A., et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the Strong Heart study. Diabetes Care 26 1 (2003) 16-23
49. Jiang R., Schulze M.B., Li T., et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 27 8 (2004) 1991-1997
50. Cromwell W.C., and Otvos J.D. Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dL. Am J Cardiol 98 12 (2006) 1599-1602
51. Brunzell J.D., Davidson M., Furberg C.D., et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31 4 (2008) 811-822
52. Howard B.V., Roman M.J., Devereux R.B., et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 299 14 (2008) 1678-1689
53. la-Korpela M., Lankinen N., Salminen A., et al. The inherent accuracy of 1H NMR spectroscopy to quantify plasma lipoproteins is subclass dependent. Atherosclerosis 190 2 (2007) 352-358
54. Cromwell W.C., and Otvos J.D. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 6 5 (2004) 381-387
55. Contois J.H., McNamara J.R., Lammi-Keefe C.J., et al. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the framingham offspring study. Clin Chem 42 4 (1996) 515-523